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Background: Only a small portion of HPV 16 infections persist and can lead to cervical intraepithelial lesions and
cancer. Factors that favour HPV persistence versus clearance are still poorly understood, but several studies have
suggested that HPV intra-type variants may influence persistence and clinical outcome. The aim of this study was to
assess the possible association between HPV 16 variants and the risk for viral persistence in the general population
of France.
Methods: One hundred and forty two women infected with HPV 16 with normal cytology, without previous
treatment for cervical lesions, and with a valid second follow-up visit 4 to 16 months later, were selected from
patients participating in routine cervical cancer screening in the Reims HPV Primary Screening Cohort Study. HPV
intra-type variants were determined by sequencing the HPV 16 E6 open reading frame, and were compared for
viral persistence at the second visit using odds ratios (OR) to estimate relative risk.
Results: Although no statistically significant differences in risk for persistence were observed by the HPV 16 variant
lineage, European variants containing the polymorphism 350 T (EUR-350 T) appeared to persist more often than
those containing 350 G (EUR-350 G) (OR = 1.6, 95% CI = 0.8-3.4).
Conclusions: No strong differences were observed in the risk of viral persistence for the HPV 16 variants that
predominate in France.
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High-risk (HR) human papillomaviruses (HPVs), are the
etiological agents of cervical cancer [1]. Even though in-
fection with an HR-HPV is frequent in sexually active
women, the majority of infections are resolved by the
immune system in 6–12 months [2]. Only a small frac-
tion of infections persist and can lead to cervical intrae-
pithelial neoplasia (CIN), which may progress to cervical
cancer. Factors that favour HPV persistence versus clear-
ance, other than HPV type itself, are still poorly under-
stood, but several studies have suggested that HPV
intra-type variants could influence persistence and clin-
ical outcome [3-8].* Correspondence: icb@iarc.fr
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reproduction in any medium, provided the orA recent proposal to define major HPV variant lineages
is by approximately 1.0% difference between full genomes
of the same HPV type, with differences of 0.5-0.9% desig-
nated as sub-lineages [9-11]. Naturally occurring genetic
variants of HPV 16 are common and have previously been
classified into 4 major lineages; European-Asian, including
the sub-lineages European (EUR), and Asian (As), African
1 (AFR1), African 2 (AFR2) and North-American/Asian-
American (NA/AA). The names of the (sub)lineages de-
rive from the geographical origin of the populations in
which they were originally isolated [12].
The most common individual polymorphism within
the European lineage is T350G in the E6 oncogene,
which leads to an amino acid change Leucine to Valine
(L83V). Thus, the European lineage can be divided into
isolates containing 350 T (EUR-350 T) or 350 G (EUR-
350 G), even though this polymorphic position does not
seem to define phylogenetic lineages [10]. Several studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ferent distribution among cervical cancer cases and con-
trols and can influence persistence [3,13,14].
The aim of this study was to assess the possible associ-
ation between the genetic variants of HPV 16 and the
risk of persistent HPV infection in the general popula-
tion in France.
Results
Sequencing results were obtained for a total of 142
women infected with HPV 16 with normal cytology and a
valid follow-up visit. The follow-up visits ranged from
minimum 4.0 months to maximum 16.0 months (median:
7.7 months, 25th percentile: 6.2 months, 75th percentile:
10.9 months). The majority of the baseline infections
belonged to the European lineage (n = 131, 92.3%), with
EUR-350 T and EUR-350 G accounting for 40.8% and
51.4% of the isolates, respectively. C109T (n = 3) was the
only other single nucleotide polymorphism (SNP) found
in more than one EUR isolate (Table 1). The number of
non-EUR isolates was small (n = 11) and consisted of
African-lineages and NA-lineage isolates (Table 1).
Of these 142 women infected with HPV 16, 86 (60.6%)
showed a persistent infection at the second visit. The
proportion of HPV 16 infections that persisted was
slightly higher for EUR-350 T (67.2%) than EUR-350 G
(56.1%) (OR = 1.6, 95% CI = 0.7-3.5), although this differ-
ence did not reach statistical significance. Adjustment
for age and time to second visit did not materially alter
this finding (OR = 1.6, 95% CI = 0.8-3.4) (Table 2).
Among the 32 HPV 16 infections that had evidence of
persistence for 12 months and more, 16 (50.0%) were
EUR-350 T and 13 (40.6%) EUR-350 G (OR versus clear-
ance =2.1, 95% CI = 0.7-5.8, data not shown).
Due to the rarity of non-European lineages a compari-
son by individual lineage could not be made. However,
the proportion of all non-European lineages combined
that persisted was similar to that for EUR-350 G (OR =
0.9, 95% CI = 0.2-3.4) (Table 2).
Discussion
There were no statistically significant differences in the
risk for persistence by HPV 16 variant lineage among
women participating to the Reims HPV Primary Screen-
ing Cohort Study between 2001 and 2008. This finding,
together with the distribution of the HPV 16 variants
among infections at baseline, is consistent with results of
a smaller and earlier study from this same cohort [14].
Nevertheless, European lineage isolates containing the
polymorphism 350 T (EUR-350 T) did appear to persist
more often than those containing 350 G (EUR-350 G)
(OR = 1.6, 95% CI = 0.8-3.4). This is consistent with the
findings of the only other population-based study of
HPV 16 variant persistence in Europe: among 261 HPV16 infections in a large cohort in Denmark, infection
with EUR-350 T was associated with a significant
increased risk for persistence at 2 years (OR versus
EUR-350 G = 2.06, 95% CI = 1.04 - 4.25) [3].
One weakness of the present study was the inability to
make any robust reflection on viral persistence of non-
EUR HPV 16 lineages, due to their rarity in the French
population [4,7,15]. Furthermore, the time-interval to de-
termine infection persistence was relatively short, driven
by the use of samples from a real-life screening practice in
which women with an HR-HPV infection with normal cy-
tology were advised to return at 6–12 months.
As a consequence of viral persistence, it would be
expected to find the EUR-350 T more often in cervical
cancer. In accordance, Zehbe et al. showed an enrich-
ment of EUR-350 T in invasive cervical cancer in the
Czech Republic, and, to a lesser extent, in Italy. How-
ever, they also found a significant under-representation
of EUR-350 T in invasive cervical cancer in Sweden [13].
This suggests that the relative oncogenic potential of
HPV 16 EUR-350 T versus EUR-350 G might be
population-specific [13].
Conclusions
Both EUR-350 T and EUR-350 G are found commonly
in precursor lesions and cervical cancers in Northern
Europe, meaning that any clinical utility of variant ana-
lysis is not yet evident. Nevertheless, understanding the
genetic basis of differences in persistence of HPV 16 var-
iants may help to unravel important interactions be-
tween HPV 16 and the host immune system. This could




Samples were selected from patients participating in the
Reims HPV Primary Screening Cohort Study conducted
in clinics and hospitals in Reims, France, and its surround-
ings [16,17]. Briefly, since 1997, women participating in
the study were offered systematic cervical cancer screen-
ing combining liquid based cytology and HR-HPV testing
by the Hybrid Capture 2 Test (Qiagen, Gaithersburg, MD
USA) when they had their routine cervical smear per-
formed. Women positive for HR-HPV or with abnormal
cytology were advised to return 6–12 months later. For re-
search purposes, since 2001, DNA has been extracted rou-
tinely from HR-HPV positive samples and screened for
HPV 16 presence. The Reims HPV Primary Screening Co-
hort Study has been approved by the French committee
“Comité de Protection des Personnes” (CPP-Est III,
Nancy), statement no DC-2008-374. All women were
informed and gave their written consent to participate in
the study.
Table 1 Nucleotide sequence variations in the HPV 16 E6 gene of 142 HPV 16-positive French women
Status HPV 16 E6 nucleotide position
Clearance* Persistence* 109 131 132 143 145 176 183 187 196 255 256 269 275 285 286 289 295 335 350 403 453 464 478 532 (sub-) lineage
N N T A G C G G T A G G C G A C T A T C T A G A C A Reference
13 29 - - - - - - - - - - - - - - - - - - - - - - - - EUR-350 T
6 6 0 0 0 0 0 0 0 0 0 0 - - - - - - - - - 0 0 0 0 0 EUR-350 T
0 1 - - - - - C - - - - - - - - - - - - - - - - - - EUR-350 T
0 1 - - - - - - - G - - - - - - - - - - - - - - - - EUR-350 T
0 1 - - - - - - - - - - - A - - - - - - - - - - - - EUR-350 T
0 1 - - - - - - - - - - - - - - - - - - - - - G - - EUR-350 T
22 27 - - - - - - - - - - - - - - - - - - G - - - - - EUR-350 G
9 9 0 0 0 0 0 0 0 0 0 0 - - - - - - - - G 0 0 0 0 0 EUR-350 G
0 3 C - - - - - - - - - - - - - - - - - G - - - - - EUR-350 G
0 1 - - - - - - - - - - - - - - - - - - G - T - - - EUR-350 G
0 1 - - - - - - - - - - - - - - - - - - G - - - A - EUR-350 G
1 0 - - - - - - - - - - - - G - - - - - G - - - - - EUR-350 G
0 1 - - - - T - - - - - - - - - A G - T G - - - - - NA (non-EUR)
1 1 - - C G T - - - - - - - - - A G - T - - - - - - AFR1 (non-EUR)
0 1 - G - G T - - - - - - - - - A G G T G - - - - - AFR1 (non-EUR)
2 1 C - T G T - - - - - - - - - A G - T - G - - - - AFR2 (non-EUR)
1 0 C - T G T - C - - - - - - - A G - T - G - - - - AFR2 (non-EUR)
0 1 C - T G T - - - - - - - - G A G - T - G - - - - AFR2 (non-EUR)
0 1 - - - G T - - - A T T - - - A G G T - - - - - - AFR2 (non-EUR)
1 0 - - - G T - - - - - - - - - A G - T - - - - - - AFR2 (non-EUR)
56 86
Sequence results are shown by outcome of infection: *Clearance (HPV16-negative at follow-up visit between 4–16 months) or *Persistence (HPV16-positive at follow-up visit between 4–16 months).
Abbreviations: EUR EURopean, NA North American, AFR AFRican.



















Table 2 Outcome of HPV 16 infection in 142 French




n (%) n (%) aOR† [95% CI]
EUR-350 G 32 (43.8) 41 (56.1) 1
EUR-350 T 19 (32.8) 39 (67.2) 1.6 [0.8 – 3.4]
Non-EUR 5 (45.5) 6 (54.5) 0.9 [0.2 – 3.4]
* Clearance = HPV 16-negative at follow-up visit; Persistence = HPV 16-positive
at follow-up visit.
† aOR: Odds Ratio adjusted for age and time interval between first and follow-
up visit.
Cornet et al. Infectious Agents and Cancer 2013, 8:4 Page 4 of 5
http://www.infectagentscancer.com/content/8/1/4For the period 2001 to 2008, HPV 16-positive women
that met the following criteria were selected: diagnosed
with normal cytology and with a valid stored DNA sample
at their first HPV 16-positive visit, without previous treat-
ment for cervical lesions, and with a valid follow-up visit
of known HPV 16 DNA between 4 to 16 months later.
These patients overlap partially (n = 21) with those
included in a previous report on HPV 16 variants from
this same cohort between 1997 and 2003 [14].HPV testing and sequencing
HPV 16 E6 variants were analysed from DNA stored
from the first HPV 16-positive normal cytology sample.
DNA was extracted from liquid-based cervical samples,
collected in PreservCyt Medium (Hologic, Marlborough,
MA USA), with the EZ1 DNA Tissue Kit on the EZ1 in-
strument (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. Samples were lysed over-
night using proteinase K at 56°C and DNA was eluted in
a 200 μL volume.
HPV 16 DNA presence was screened initially by a spe-
cific HPV 16 E6/E7 Taqman real-time polymerase chain
reaction (PCR) and confirmed by either the Linear Array
HPV Genotyping Test (Roche Molecular Diagnostics,
Branchburg, NJ USA) or the Inno-Lipa Extra HPV
Genotyping Test (Innogenetics, Gent, Belgium).
The PCR and sequencing of the HPV 16 E6 gene was
performed as described by Gheit et al. 2011 [3]. If ampli-
fication of the whole HPV 16 E6 failed, a shorter frag-
ment of E6 (nt. 256 – 400) was amplified with the
primers: 5’- GACTTTGCTTTTCGGGATT -3’ and 5’-
GGCTTTTGACAGTTAATAC -3’. The sequences were
analyzed using the Blast function from PubMed and sin-
gle nucleotide polymorphisms (SNP) were identified
using the prototype HPV 16 sequence described by
Myers et al. [18]. Novel SNPs were confirmed by a sec-
ond, independent PCR and sequencing reaction. Data
were validated by comparing the SNPs reported by visual
inspection in Blast with the output files from the DNA
sequencer, using an ad hoc designed computer program.Statistical analysis
The HPV 16 infection was defined as persistent if the
woman was still HPV 16-positive at the next follow-up
visit. Relative risks for persistence were compared be-
tween EUR-350 T, EUR-350 G, and non-European
lineages, using odds ratios (OR) and corresponding 95%
confidence intervals (CI). ORs were adjusted for age
(<28 and 28+ years) and the duration between two visits
(<8 and 8+ months).
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